Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trialBruce Cree, Jeffrey L. Bennett, Orhan Aktaş et al.|The Lancet Neurology|2024Cited by 54
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktaş, Bruce Cree, Hans‐Peter Hartung et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 47
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Bruce Cree, Jeffrey L. Bennett et al.|Neurology Neuroimmunology & Neuroinflammation|2021Cited by 42
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialJeffrey L. Bennett, Bruce Cree, Orhan Aktaş et al.|EBioMedicine|2022Cited by 42
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Bruce Cree, Sean J Pittock et al.|Multiple Sclerosis and Related Disorders|2021Cited by 37